论文信息 - Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series - 字舞流文

Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series

E. Campo | D. Costa | R. Coutinho | B. Nomdedeu | C. Muñoz | A. Carrió | Ana Vidal | Mohammed Belkaid

[1] J. Maciejewski,et al. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. , 2008, Cancer genetics and cytogenetics.

[2] D. Haase. Cytogenetic features in myelodysplastic syndromes , 2008, Annals of Hematology.

[3] G. Mufti,et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes , 2008, Annals of Hematology.

[4] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[5] A. Giagounidis,et al. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses , 2006, Annals of Hematology.

[6] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[7] D. Steensma,et al. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. , 2005, Mayo Clinic proceedings.